Recently, the Ministry of Health convened a work conference for 2011 to clarify the development goals of the medical and health undertakings in 2011 and the next five years. We believe that the three major highlights of accelerating the reform of public hospitals, preventing and controlling major diseases, and strengthening medical services will become the latest trend in the development of the pharmaceutical industry in 2011. It is estimated that the main business revenues of pharmaceutical manufacturing, chemical raw material pharmaceuticals, pharmaceutical preparations, proprietary Chinese medicines, and biological products will increase by 25%, 22%, and 23% year-on-year in 2011, respectively. %, 26%, 31%. With the recent decline in the market value of the industry and the increase in profitability, the pharmaceutical industry is once again “cheap†and can carefully monitor investment opportunities based on risk control.
Public Hospital Reform Opens Industry Development Space
At the beginning of the new year, the Ministry of Health explicitly proposed to accelerate the pilot reform of public hospitals and determine that a number of key policy measures that are easy to operate and have matured experience be promoted throughout the country, and that the government will directly increase support for public hospital reform by adding 300 billion yuan in funds at the beginning of the year. This will open up New development space for the industry.
In accordance with the principles of public hospital reforms of "up and down linkage, internal vitality, and external thrust," China will promote measures to facilitate the benefit of the people throughout the country so that the people can enjoy convenient medical services as soon as possible. Strengthen the planning and management of medical institutions, optimize the layout and structure of public hospitals, and organize the implementation of pilots for setting up regional medical centers. At the same time, China will give priority to the development of county-level hospitals, and select 300 county hospitals covering counties with more population and better foundations to carry out comprehensive reform pilots. We will improve the orderly and standardized policies for guiding medical treatment and accelerate the establishment of a division of labor and cooperation mechanism between public hospitals and primary health care institutions. In addition, China will gradually implement the first consultation in the community to establish a two-way referral system for urban community health service agencies and large hospitals. The implementation of quality care services, appointments for medical treatment, first consultation after treatment settlement, volunteer hospital services, convenience clinics and other measures to facilitate the people. Continue to develop common and frequently-occurring clinical pathways, and expand the clinical pathway to implement coverage.
It is worth noting that China will also actively explore the reform of the payment system, improve policy measures, appropriately raise the level of treatment for medical personnel, and expand the scope of trials for doctors practicing more medical practice and assistant practitioners for township doctors. Actively explore major experimental reforms of institutional mechanisms. The pilot cities will be promoted to carry out comprehensive reforms and explore difficult issues such as separation of government affairs, separation of management from management, separation of medicines, profitability and non-profit separation. Actively promote the public hospitals to pay for the reform of the system as an entry point to solve the medicine to supplement the practice of medicine. Improve the classification management system of medical institutions, encourage, support and guide social capital to develop medical and health services to meet the multi-level needs of the masses. The implementation of measures to facilitate the benefit of the people will be combined with the promotion of comprehensive reforms and the exploration of solutions to institutional problems, so that the people will enjoy the fruits of reforms. We believe that public hospital reform will significantly benefit listed companies in medical devices and holding hospitals.
Equalization guarantees rapid development of the vaccine industry
We have noticed that the promotion of gradual equalization of basic public health services and the solid implementation of health emergencies, prevention and control of major diseases, and maternal and child health work have been mentioned in the work priorities of 2011 and the next five years. As the vaccine industry plays an important role in the prevention and control of major diseases, it will continue to achieve an average annual high growth of 25% to 30%.
The data shows that China is the world’s largest vaccine producer and the country with the largest number of vaccine product manufacturers in the world. It has an annual output of 1 billion vaccines, which are used to prevent hepatitis B, polio, measles, whooping cough, diphtheria, and tetanus. The number of vaccines for common diseases has reached 500 million people and all of them have achieved planned immunization. Due to the structure and management of the healthcare system in China, the vaccine market is divided into the planned immunization vaccine market and the valuable vaccine market, with an approximate ratio of 7:3. Planned immunization vaccines are purchased by the government for tendering, with low prices and low profits. The market is basically stable and is currently supplied by domestic vaccine manufacturers. Valuable vaccines are voluntary vaccines voluntarily selected by vaccinates who are not included in the scope of national plan immunization. Inoculated by consumers at their own expense, such vaccines have high prices and high profits. Current unplanned vaccines are basically controlled by international giants such as GlaxoSmithKline, Sanofi-Aventis and Novartis. The domestic competition pattern is that the six research institutes of the China Sheng Group (Beijing, Lanzhou, Changchun, Wuhan, Shanghai, and Chengdu) and the Hualan Biology and Medical Research Institute Kunming have long dominated the industry. Other companies actively participate in the vaccine industry in the future. Development, related opportunities deserve attention.
Strengthening medical services to boost therapeutic new technology companies
The Ministry of Health also proposed to strengthen medical quality management. Promote the construction of national medical quality control and control centers and key clinical specialty national medical quality and control centers; continue to promote the mutual recognition of results of auxiliary inspections at the same level of medical institutions; strengthen the clinical application management of medical technology; identify and implement national clinical focus specialists and priorities Cultivate specialist construction projects to improve our country's expertise in medical services. Strengthen the management of medical affairs in medical institutions, study the establishment of access systems for clinical pharmacists, and promote the rational use of drugs in clinical practice. We believe that therapeutic new technology listed companies, represented by molecular-targeted technologies, will usher in certain opportunities.
With the aid of modern scientific and technological means, people's understanding and treatment of tumors has reached the cellular, molecular and genetic levels. At the same time, with the rapid development of materials science, computer technology, and digital imaging technology, the combination of biomedical engineering technology and clinical oncology diagnosis and treatment technology has become more and more closely, resulting in a number of targeted cancer treatment technologies. With the continuous promotion of tumor-targeted therapeutic technology and continuous improvement in therapeutic efficacy, the concept of individualized, targeted and comprehensive treatment of tumors has continuously been recognized by academic circles at home and abroad. From the point of view of international investment, we can pay close attention to leading listed companies such as GSK, PFE, and Kexing Biological.
Public Hospital Reform Opens Industry Development Space
At the beginning of the new year, the Ministry of Health explicitly proposed to accelerate the pilot reform of public hospitals and determine that a number of key policy measures that are easy to operate and have matured experience be promoted throughout the country, and that the government will directly increase support for public hospital reform by adding 300 billion yuan in funds at the beginning of the year. This will open up New development space for the industry.
In accordance with the principles of public hospital reforms of "up and down linkage, internal vitality, and external thrust," China will promote measures to facilitate the benefit of the people throughout the country so that the people can enjoy convenient medical services as soon as possible. Strengthen the planning and management of medical institutions, optimize the layout and structure of public hospitals, and organize the implementation of pilots for setting up regional medical centers. At the same time, China will give priority to the development of county-level hospitals, and select 300 county hospitals covering counties with more population and better foundations to carry out comprehensive reform pilots. We will improve the orderly and standardized policies for guiding medical treatment and accelerate the establishment of a division of labor and cooperation mechanism between public hospitals and primary health care institutions. In addition, China will gradually implement the first consultation in the community to establish a two-way referral system for urban community health service agencies and large hospitals. The implementation of quality care services, appointments for medical treatment, first consultation after treatment settlement, volunteer hospital services, convenience clinics and other measures to facilitate the people. Continue to develop common and frequently-occurring clinical pathways, and expand the clinical pathway to implement coverage.
It is worth noting that China will also actively explore the reform of the payment system, improve policy measures, appropriately raise the level of treatment for medical personnel, and expand the scope of trials for doctors practicing more medical practice and assistant practitioners for township doctors. Actively explore major experimental reforms of institutional mechanisms. The pilot cities will be promoted to carry out comprehensive reforms and explore difficult issues such as separation of government affairs, separation of management from management, separation of medicines, profitability and non-profit separation. Actively promote the public hospitals to pay for the reform of the system as an entry point to solve the medicine to supplement the practice of medicine. Improve the classification management system of medical institutions, encourage, support and guide social capital to develop medical and health services to meet the multi-level needs of the masses. The implementation of measures to facilitate the benefit of the people will be combined with the promotion of comprehensive reforms and the exploration of solutions to institutional problems, so that the people will enjoy the fruits of reforms. We believe that public hospital reform will significantly benefit listed companies in medical devices and holding hospitals.
Equalization guarantees rapid development of the vaccine industry
We have noticed that the promotion of gradual equalization of basic public health services and the solid implementation of health emergencies, prevention and control of major diseases, and maternal and child health work have been mentioned in the work priorities of 2011 and the next five years. As the vaccine industry plays an important role in the prevention and control of major diseases, it will continue to achieve an average annual high growth of 25% to 30%.
The data shows that China is the world’s largest vaccine producer and the country with the largest number of vaccine product manufacturers in the world. It has an annual output of 1 billion vaccines, which are used to prevent hepatitis B, polio, measles, whooping cough, diphtheria, and tetanus. The number of vaccines for common diseases has reached 500 million people and all of them have achieved planned immunization. Due to the structure and management of the healthcare system in China, the vaccine market is divided into the planned immunization vaccine market and the valuable vaccine market, with an approximate ratio of 7:3. Planned immunization vaccines are purchased by the government for tendering, with low prices and low profits. The market is basically stable and is currently supplied by domestic vaccine manufacturers. Valuable vaccines are voluntary vaccines voluntarily selected by vaccinates who are not included in the scope of national plan immunization. Inoculated by consumers at their own expense, such vaccines have high prices and high profits. Current unplanned vaccines are basically controlled by international giants such as GlaxoSmithKline, Sanofi-Aventis and Novartis. The domestic competition pattern is that the six research institutes of the China Sheng Group (Beijing, Lanzhou, Changchun, Wuhan, Shanghai, and Chengdu) and the Hualan Biology and Medical Research Institute Kunming have long dominated the industry. Other companies actively participate in the vaccine industry in the future. Development, related opportunities deserve attention.
Strengthening medical services to boost therapeutic new technology companies
The Ministry of Health also proposed to strengthen medical quality management. Promote the construction of national medical quality control and control centers and key clinical specialty national medical quality and control centers; continue to promote the mutual recognition of results of auxiliary inspections at the same level of medical institutions; strengthen the clinical application management of medical technology; identify and implement national clinical focus specialists and priorities Cultivate specialist construction projects to improve our country's expertise in medical services. Strengthen the management of medical affairs in medical institutions, study the establishment of access systems for clinical pharmacists, and promote the rational use of drugs in clinical practice. We believe that therapeutic new technology listed companies, represented by molecular-targeted technologies, will usher in certain opportunities.
With the aid of modern scientific and technological means, people's understanding and treatment of tumors has reached the cellular, molecular and genetic levels. At the same time, with the rapid development of materials science, computer technology, and digital imaging technology, the combination of biomedical engineering technology and clinical oncology diagnosis and treatment technology has become more and more closely, resulting in a number of targeted cancer treatment technologies. With the continuous promotion of tumor-targeted therapeutic technology and continuous improvement in therapeutic efficacy, the concept of individualized, targeted and comprehensive treatment of tumors has continuously been recognized by academic circles at home and abroad. From the point of view of international investment, we can pay close attention to leading listed companies such as GSK, PFE, and Kexing Biological.
Concrete Building Flour Milling Plant
Wheat Flour Milling Plant,Wheat Flour Making Machine,Wheat Milling Machine,Wheat Flour Milling Machine
HEBEI PINGLE FLOUR MACHINERY GROUP CO., LTD , https://www.plrollermill.com